Pharmaceutical

AbbVie licenses OSE’s chronic inflammation therapy for $48m upfront

AbbVie will pay $48m in upfront costs and up to $665m in milestone payments to license OSE’s monoclonal antibody OSE-230.

Feb 28, 2024 - 18:00
AbbVie licenses OSE’s chronic inflammation therapy for $48m upfront
AbbVie will pay $48m in upfront costs and up to $665m in milestone payments to license OSE’s monoclonal antibody OSE-230.
Read the original article

Tags:

Previous Article

EMA and FDA green-light MoonLake to advance IL-17 inhibitor

Next Article

Biogen discontinues Aduhelm to focus on Leqembi for Alzheimer’s disease

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Patient with rare neurodegenerative disorder improves with non-profit’s ASO therapy

Patient with rare neurodegenerative disorder improves w...

Aug 13, 2024

GSK’s Omjjara gains approval in Japan for myelofibrosis treatment

GSK’s Omjjara gains approval in Japan for myelofibrosis...

Jun 26, 2024

CDC and social media: The new misinformation war

CDC and social media: The new misinformation war

Feb 7, 2024